Contact UsInvestorsCareersMediaScienceContact Us
HomeOur VoiceOur Environmental, Social and Governance (ESG) Performance

Thursday, April 8, 2021

Pfizer Inc recently published its first-ever Environmental, Social and Governance (ESG) Report, which builds on our prior Corporate Responsibility Reports and our long history of social responsibility.

In a year unlike any other, Pfizer’s purpose-driven commitment to patients and the broader needs of society have never been more urgent. In the face of simultaneous health, economic and culture crises, we took bold steps in 2020 to address the needs of all stakeholders.

Pfizer’s inaugural ESG Report represents a new chapter in Pfizer’s commitment to enhance stakeholder awareness of our priority ESG issues and disclose how our performance on non-financial metrics is contributing to long-term value creation and a sustainable, responsible, and patient-centric business model.

Our 2020 global highlights include:

  • Pfizer progressed our COVID-19 vaccination trials at the speed of science while remaining grounded in the importance of public trust and our commitment to equitable distribution. We will work with the COVAX facility to facilitate equitable access to our COVID vaccine to eligible countries, with support from partners at the global and local levels.

  • We were the first biopharmaceutical company to issue a Sustainability Bond ($1 billion+), the proceeds of which are earmarked for environmental and social initiatives. Proceeds are being allocated to enhance our ability to reach more women and children in low-income countries, address antimicrobial resistance, strengthen health care infrastructure and help manage our environmental impact.

  • We doubled down on our Infectious Disease (I.D.) Impact Initiative, Pfizer’s long-term global health commitment to redefine the way we fight infectious disease and help protect underserved people around the world from these deadly threats.

  • We set concrete goals to address systemic racism and gender equity challenges by reviewing and augmenting our plans to increase diversity and opportunity parity. Specifically, in Canada, we aim to have 50% of our Country Leadership Council composed of women by 2023 and 30% of under-represented groups. We also aim to have 30% of our workforce representing racial minorities and to increase the number of indigenous new colleagues.

  • Pfizer has long recognized the societal impacts from environmental issues such as climate change. We successfully achieved our 2020 environmental goals and made a commitment to become carbon neutral across our company’s operations by 2030. The Science Based Targets Initiative (SBTi) has commended Pfizer's 2030 Scope 1 & 2 greenhouse gas (GHG) emission goal as an ambitious 1.5°C-aligned target.

  • The improvement of our standing on the Access to Medicine Index to fourth place in 2021 from 11th in 2018 underscores our commitment to access and equity in health care. For example, through our ex-U.S. patient assistance programs, we were able to reach nearly 700,000 patients in 2020, some of whom may not have otherwise been reached through traditional commercial channels. In total, we reached more than 58 million patients through access and affordability programs.

We look forward to sharing more progress against the global benchmarks that we have set against these important ESG issues.

Young Leader Inspires and Engages Pfizer Canada Colleagues 

Drug Shortage Lessons Learned: How do we build a more resilient injectable medicines market in Canada?

Our Environmental, Social and Governance (ESG) Performance

Advancing Diversity at Pfizer Canada

The importance of supporting a resilient life sciences eco-system in Canada

Pfizer Highlights Commitment to All Patients During Patients in Focus Week

“My Voice, Our Equal Future”

In My Words: Effie’s Life with Ulcerative Colitis

Unleashing the power of its people makes Pfizer a top employer

Hope and Optimism While Living With Ulcerative Colitis

Marking Rare Disease Day 2022: Why Every Minute Matters 

In Conversation with Barry Stein

In Conversation with Filomena Servidio-Italiano

A commitment to creating a culture of inclusivity at Pfizer Canada

Pfizer announces recipients of research grants focused on transthyretin amyloid cardiomyopathy in Canada 

Canada’s Research-Based Pharmaceutical Industry is a Significant Contributor to the Economy

World Hemophilia Day: Robbie’s journey highlights the importance of raising awareness and finding community

Listening and Learning from Patients Living with Bladder Cancer

Pfizer Canada’s recommendations regarding the development of a National Strategy for Drugs for Rare Diseases

A Conversation with Najah Sampson

Living Well with Rheumatoid Arthritis (RA): Getting to the Heart of the Matter

Vaccine And Immunization Facts

Understanding Biosimilars

Girls Belong Here at Pfizer Canada

Giving Back – Pfizer Canada’s Month of Giving 

Pfizer Colleagues Get Healthy with the VIVA Health & Wellness program

Carpe Diem: Rise in Remote Connecting a Boon for those Living with RA

Imagine RA Network: Chronic Illness in a Pandemic Life

CDHF and Pfizer: The power of collaboration in the ulcerative colitis space

Reflecting on Rare Disease Day 2021

A Day in the Life with Atopic Dermatitis by Pfizer Colleague Kerri
About UsOur ProductsHelping Communities Our Voice Suppliers Distribution ChannelPfizer WorldwideMedia CentreTerms Of Use Careers Healthcare ProfessionalsContact UsPrivacy PolicyCopyright © Pfizer Canada 2022 All rights reserved. The information is intended only for residents of Canada. ® Pfizer Inc, used under license